NEW YORK (360Dx) – TearLab will pursue initial US Food and Drug Administration clearance of a test card measuring a single inflammatory biomarker, MMP-9, in combination with the firm’s FDA-cleared osmolarity test, instead of two biomarkers plus osmolarity, as originally planned. The timing of the filing for FDA clearance is not expected to change, TearLab said, adding it still anticipates filing its FDA submission by the end of 2017.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.